GMED vs PEN
Globus Medical vs Penumbra, Inc. — AI-powered side-by-side comparison
GMED
Globus Medical
71
Buy
VS
PEN
Penumbra, Inc.
67
Buy
| Metric | GMED | PEN |
|---|
| AI Score |
71
|
67
|
| Price |
$85.12
|
$326.07
|
| P/E Ratio |
21.45×
|
79.78×
|
| ROE |
11.8%
|
12.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.5%
|
67.8%
|
| Debt / Equity |
0.02×
|
0.14×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
75.9
|
79.6
|
| Beta |
0.954
|
0.701
|
| Expected Upside |
+0.1%
|
+6.3%
|
AI Committee View
Current Innellis committee reasoning for GMED versus PEN.
GMED leads by 4 points.
GMED scores 71/100 (Buy) versus PEN at 67/100 (Buy).
GMED Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 76 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 76 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
PEN Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 consecutive earnings misses -- execution concerns. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- 2 consecutive earnings misses -- execution concerns — Growth
- RSI at 80 is in overbought territory — Technical